Efficacy and toxicity with radiation field designs and concurrent temozolomide for CNS lymphoma.
Anna Mary Brown LaucisKatherine SelwaYilun SunMichelle M KimKyle C CuneoTheodore S LawrenceDaniel R WahlLarry JunckYoshie UmemuraPublished in: Neuro-oncology practice (2022)
In this study, concurrent temozolomide with radiotherapy in CNS lymphoma was associated with better PFS and was well tolerated. Low-dose WBRT with a boost is a safe and reasonable treatment approach for focal refractory disease. Prospective research that includes rigorous neurocognitive assessments is now warranted.